huTfR1-CHO-K is primarily used in targeted drug delivery research, especially in oncology and neurological disease studies. It enables specific binding to transferrin receptors overexpressed on cancer cells and the blood-brain barrier, facilitating the transport of therapeutic agents into tumor tissues or across the central nervous system. This molecule is instrumental in developing antibody-drug conjugates (ADCs) and bi-specific antibodies, enhancing the precision of treatments while minimizing off-target effects. It is also employed in diagnostic imaging to detect tumor progression and monitor receptor expression levels in preclinical models.